Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
68 hedge funds and large institutions have $16.1M invested in Lumos Pharma, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 22 reducing their positions, and 20 closing their positions.
7,700% more call options, than puts
Call options by funds: $156K | Put options by funds: $2K
17% less funds holding
Funds holding: 82 → 68 (-14)
35% less capital invested
Capital invested by funds: $24.7M → $16.1M (-$8.53M)
41% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 22
55% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.13M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$555K |
| 3 |
Goldman Sachs
New York
|
+$350K |
| 4 |
Renaissance Technologies
New York
|
+$345K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$239K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.15M |
| 2 |
State Street
Boston,
Massachusetts
|
-$840K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$802K |
| 4 |
JP Morgan Chase
New York
|
-$448K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$421K |
LUMO Hedge Fund Activity: Q2 2019 in Review
68 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q2 2019, worth a combined $16.1M — down 35% from $24.7M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of LUMO and 9 opened new positions — a net loss of 11 holders — while 22 trimmed existing stakes and 13 added.
The largest buyer was Millennium Management, adding an estimated $1.13M. The largest seller was BlackRock, cutting an estimated $2.15M.
- 68 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q2 2019, down from 82 in Q1 2019.
- Funds reported $16.1M of Lumos Pharma, Inc. Common Stock stock for Q2 2019, down 35% quarter-over-quarter.
- 9 funds opened new Lumos Pharma, Inc. Common Stock positions in Q2 2019 and 20 closed out, a net change of -11 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q2 2019 was Millennium Management, an estimated $1.13M added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q2 2019 was BlackRock, an estimated $2.15M sold.
Based on aggregated 13F filings for Q2 2019.